At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)
The University of Texas Health Science Center at San Antonio·interventional·Posted Dec 7, 2016·Updated Dec 18, 2019
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin and Placebo for Type II; Diabetes. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II; Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartSep 2017
Primary CompletionNov 2018
Study CompletionNov 2019
TodayJul 2026
First PostedDec 7, 2016
Enrollment StartSep 6, 2017
Primary CompletionNov 16, 2018
Study CompletionNov 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.6 years ago
Interventions
Dapagliflozindrug
Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
Placebodrug
Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.